The US Food and Drug Administration (FDA) has granted final approval to Breckenridge Pharmaceutical Inc, a subsidiary of Laboratorios Pen, SA, for its Abbreviated New Drug Application (ANDA) for Asenapine Sublingual Tablets in 2.5mg and 10mg strengths (generic for Saphris), it was reported on Friday.
Breckenridge Pharmaceutical is planning to introduce these strengths immediately.
The FDA has granted tentative approval for the 5mg strength. The product was developed in partnership with MSN Laboratories Private Limited. The product is intended for the treatment of mental/mood disorders.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream